{
  "meta": {
    "title": "96_Coagulation_Disorders",
    "url": "https://brainandscalpel.vercel.app/96-coagulation-disorders-e852d645.html",
    "scrapedAt": "2025-11-30T12:29:20.991Z"
  },
  "questions": [
    {
      "text": "An isolated prolongation of prothrombin time was seen in a patient with chronic liver disease. What does this suggest?",
      "choices": [
        {
          "id": 1,
          "text": "Factor VII deficiency"
        },
        {
          "id": 2,
          "text": "Factor XII deficiency"
        },
        {
          "id": 3,
          "text": "Factor XI deficiency"
        },
        {
          "id": 4,
          "text": "Factor VIII deficiency"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Isolated PT prolongation</strong> suggests <strong>factor VII deficiency.&nbsp;</strong>It can be an inherited or acquired condition (chronic liver disease).</p>\n<div id=\"pdf_viewer\" class=\"p-pdf_viewer__content\">\n<div class=\"p-pdf_iframe__page\" aria-label=\"Page 1\" data-page-number=\"1\">\n<div class=\"textLayer\">\n<table>\n<tbody>\n<tr>\n<td><strong>&nbsp;Test</strong></td>\n<td><strong><span dir=\"ltr\" role=\"presentation\">Used to assess</span></strong></td>\n<td><strong><span dir=\"ltr\" role=\"presentation\">Activated on </span></strong><br role=\"presentation\" /><strong><span dir=\"ltr\" role=\"presentation\">exposure to</span></strong></td>\n<td><strong><span dir=\"ltr\" role=\"presentation\">Normal </span></strong><br role=\"presentation\" /><strong><span dir=\"ltr\" role=\"presentation\">value</span></strong></td>\n</tr>\n<tr>\n<td><span dir=\"ltr\" role=\"presentation\">PT</span></td>\n<td>\n<p><span dir=\"ltr\" role=\"presentation\">Extrinsic </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">pathway (factor </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">VII)</span></p>\n<p><span dir=\"ltr\" role=\"presentation\">Common </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">pathway (factors </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">I, II, V, X)</span></p>\n</td>\n<td><span dir=\"ltr\" role=\"presentation\">Tissue factor</span></td>\n<td>12-16s</td>\n</tr>\n<tr>\n<td><span dir=\"ltr\" role=\"presentation\">aPTT</span></td>\n<td>\n<p><span dir=\"ltr\" role=\"presentation\"> Intrinsic </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">pathway (factors </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">VIII, IX, XI, XII) </span></p>\n<p><span dir=\"ltr\" role=\"presentation\">Common </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">pathway (factors </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">I, II, V, X)</span></p>\n</td>\n<td><span dir=\"ltr\" role=\"presentation\">Activators </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">(silica, </span><br role=\"presentation\" /><span dir=\"ltr\" role=\"presentation\">kaolin)</span></td>\n<td>26-34s</td>\n</tr>\n<tr>\n<td><span dir=\"ltr\" role=\"presentation\">TT</span></td>\n<td><span dir=\"ltr\" role=\"presentation\">Fibrinogen levels</span></td>\n<td><span dir=\"ltr\" role=\"presentation\">Thrombin</span></td>\n<td>15-19s</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4044",
      "difficulty": "easy"
    },
    {
      "text": "Prolonged aPTT and normal PT are seen in patients with all of the following except?",
      "choices": [
        {
          "id": 1,
          "text": "Hemophilia B"
        },
        {
          "id": 2,
          "text": "Lupus anticoagulant"
        },
        {
          "id": 3,
          "text": "Von Willebrand disease"
        },
        {
          "id": 4,
          "text": "Disseminated intravascular coagulation"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Disseminated intravascular coagulation is associated with <strong>prolonged PT</strong> and <strong>prolonged aPTT.</strong></p>\n<p>Conditions with prolonged aPTT can be classified on the basis of the <strong>bleeding symptoms</strong>:</p>\n<ul>\n<li>No bleeding symptoms: deficiency of Factor XII, prekallikrein, HMW kininogen, lupus anticoagulant</li>\n<li>Mild bleeding symptoms: Factor XI deficiency</li>\n<li>Severe bleeding symptoms: Hemophilia, von Willebrand disease</li>\n</ul>\n<p><strong>Lupus anticoagulant </strong>is an antiphospholipid antibody that interferes with <strong>aPTT test</strong> and causes its prolongation.&nbsp;It is<strong> corrected</strong>&nbsp;by<strong>&nbsp;</strong>adding&nbsp;<strong>excess phospholipid.</strong></p>\n<p>The clinical manifestation of lupus anticoagulant is<strong> thrombosis</strong>.&nbsp;Confirmatory tests are dilute <strong>Russell's viper venom test</strong> and <strong>k</strong><strong>aolin clotting time.</strong></p><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1969",
      "difficulty": "medium"
    },
    {
      "text": "Laboratory investigations done in a chronic alcoholic patient are given below. Which of the following clotting factors is most likely to be normal in this patient?<div class='question-desc-html'><p>Albumin - 3 g/dL</p>\n<p>PT - 20 s</p>\n<p>aPTT - 40 s</p></div>",
      "choices": [
        {
          "id": 1,
          "text": "Factor II"
        },
        {
          "id": 2,
          "text": "Factor VII"
        },
        {
          "id": 3,
          "text": "Factor VIII"
        },
        {
          "id": 4,
          "text": "Factor XI"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>All <strong>clotting factors</strong> are likely to be <strong>abnormal</strong> <strong>except factor VIII.</strong></p>\n<p>The liver is the site of production of the following factors:</p>\n<ul>\n<li>Fibrinogen (factor I)</li>\n<li>Thrombin (factor II)</li>\n<li>Factor V</li>\n<li>Factor VII (shortest half-life, hence PT affected first)</li>\n<li>Factor IX</li>\n<li>Factor X</li>\n<li>Factor XI</li>\n</ul>\n<p><strong>Factor VIII </strong>is produced in the <strong>endothelial cells</strong> and factor XIII A-subunit is produced in the bone marrow.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1971",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is the most common disorder of coagulation?",
      "choices": [
        {
          "id": 1,
          "text": "Hemophilia A"
        },
        {
          "id": 2,
          "text": "Hemophilia B"
        },
        {
          "id": 3,
          "text": "von Willebrand disease"
        },
        {
          "id": 4,
          "text": "Hemorrhagic diathesis of liver disease"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Hemorrhagic diathesis of liver</strong> disease is the <strong>most common </strong>disorder of coagulation among the given options. It is the increased tendency of spontaneous bleeding associated with fulminant or end-stage liver disease.&nbsp;</p>\n<p><strong>Acquired deficiencies</strong> of plasma coagulation factors are<strong> more frequent</strong> than congenital disorders. The most common acquired disorders include:</p>\n<ul>\n<li>Hemorrhagic diathesis of liver disease</li>\n<li>Disseminated intravascular coagulation (DIC)</li>\n<li>Vitamin K deficiency.</li>\n</ul>\n<p><strong>Hemophilia A</strong> is the <strong>most common inherited disorder</strong> of coagulation. Hemophilia A is more common than Hemophilia B.</p>\n<p>von Willebrand disease is the most common bleeding disorder.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1977",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following conditions are matched correctly with their mode of inheritance?",
      "choices": [
        {
          "id": 1,
          "text": "Factor VII deficiency - X linked recessive"
        },
        {
          "id": 2,
          "text": "Factor VIII deficiency - autosomal recessive"
        },
        {
          "id": 3,
          "text": "Factor IX deficiency - X linked recessive"
        },
        {
          "id": 4,
          "text": "Factor V deficiency - autosomal dominant"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Factor IX deficiency</strong> (hemophilia B) is inherited as an <strong>X-linked recessive trait</strong>.</p>\n<p>Hemophilia is an X-linked recessive hemorrhagic disease due to mutations in:</p>\n<ul>\n<li><strong>Factor VIII gene</strong> (hemophilia A or classic hemophilia) -80% more common than hemophilia B&nbsp;</li>\n<li><strong>Factor IX gene</strong> (hemophilia B)</li>\n</ul>\n<p>Clinically, hemophilia A and hemophilia B are<strong> indistinguishable</strong>.</p>\n<p>All clotting factor deficiencies except hemophilia are inherited as<strong> autosomal recessive</strong>.</p>\n<p>Inherited coagulation disorders treatment:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Blood components</strong></td>\n<td><strong>Composition</strong></td>\n<td><strong>Indications</strong></td>\n</tr>\n<tr>\n<td>Factor VIII concentrates</td>\n<td>Factor VIII</td>\n<td>Hemophilia&nbsp;A</td>\n</tr>\n<tr>\n<td>Factor IX concentrates</td>\n<td>Factor IX</td>\n<td>Hemophilia B</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>\n<p>Fibrinogen</p>\n<p>Factor XIII</p>\n<p>Factor&nbsp;VIII</p>\n<p>VWF</p>\n</td>\n<td>\n<p>Fibrinogen deficiency, factor XIII deficiency, von Willebrand disease</p>\n</td>\n</tr>\n<tr>\n<td>Fresh Frozen Plasma (FFP)</td>\n<td>\n<p>Coagulation factors</p>\n<p>Protein C</p>\n<p>Protein&nbsp; S</p>\n<p>Antithrombin</p>\n</td>\n<td>\n<p>Deficiency of prothrombin, factor V, factor VII, factor X, factor XI</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4017",
      "difficulty": "medium"
    },
    {
      "text": "The most common bleeding manifestation seen in severe hemophilia is:",
      "choices": [
        {
          "id": 1,
          "text": "Recurrent hematomas"
        },
        {
          "id": 2,
          "text": "Recurrent hemarthrosis"
        },
        {
          "id": 3,
          "text": "Hematuria"
        },
        {
          "id": 4,
          "text": "Intracranial hemorrhage"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Recurrent hemarthrosis</strong> is the <strong>most common</strong> bleeding manifestation of <strong>severe</strong> hemophilia.&nbsp;Hemophilia is said to be severe when the residual activity of factor VIII is <strong>&lt;1%</strong>.</p>\n<p>Hemophilia is an <strong>X-linked recessive </strong>hemorrhagic disorder and is caused by mutations in either the <strong>F8 gene (hemophilia A</strong> or classic hemophilia) or the<strong> F9 gene (hemophilia B).</strong> Clinically, it is impossible to distinguish between hemophilia A and hemophilia B as they present with <strong>similar symptoms. </strong>It can be classified based on residual activity of <strong>FVIII </strong>or<strong>&nbsp;FIX</strong> as severe (&lt;1%), moderate (1&ndash;5%), or mild (6&ndash;30% )&nbsp;</p>\n<p>Hemophilia presents early in life- <strong>bleeding after circumcision</strong> or when beginning to walk or crawl.</p>\n<p>Clinical features:</p>\n<ul>\n<li>Acute hemarthrosis:\n<ul>\n<li>Local pain, swelling</li>\n<li>Erythema</li>\n<li>Muscle contractures due to fixed positioning.</li>\n</ul>\n</li>\n<li>Chronic hemarthrosis:\n<ul>\n<li>Synovial thickening</li>\n<li>Synovitis (due to intraarticular blood)</li>\n</ul>\n</li>\n</ul>\n<p>The most common joint affected is the<strong> knee</strong>. One joint is affected more than the other. This is called the <strong>target joint</strong>. Muscle hematomas can lead to compartment syndromes.</p>\n<p>Hematuria is common but self-limited. Life-threatening bleeds such as bleeding into oropharyngeal spaces, CNS, and retroperitoneum can occur.</p>\n<p><strong>Treatment:</strong> Without treatment, severe hemophilia may limit life expectancy. <strong>Factor replacement</strong> for hemophilia has been the mainstay of therapy.</p>\n<ul>\n<li><strong>FVIII dose (IU)</strong> = Target FVIII levels &ndash; FVIII baseline levels &times; body weight (kg) &times; 0.5 unit/kg&nbsp; .</li>\n<li><strong>FIX dose (IU)</strong> = Target FIX levels &ndash; FIX baseline levels &times; body weight (kg) &times; 1 unit/kg&nbsp;</li>\n</ul>\n<p>The FVIII half-life of 8&ndash;12 h requires injections twice a day to maintain therapeutic levels, whereas the FIX half-life is longer, ~24 h so that once-a-day injection is sufficient.&nbsp;</p>\n<p>&nbsp;</p><hr><h3>Related Pearl: Differences between Bleeding Disorders and Coagulation disorders</h3><table>\n<tbody>\n<tr>\n<td><strong>Finding</strong></td>\n<td><strong>Bleeding disorders</strong></td>\n<td><strong>Coagulation disorders</strong></td>\n</tr>\n<tr>\n<td>Cause</td>\n<td>\n<p>Quantitative/ Qualitative platelet abnormality</p>\n</td>\n<td>Deficiency of clotting factors</td>\n</tr>\n<tr>\n<td>Sex</td>\n<td>More common in females (commonly autoimmune)</td>\n<td>More common in males (commonly X-linked)</td>\n</tr>\n<tr>\n<td>Family history</td>\n<td>Rare (except in VWD)</td>\n<td>Common</td>\n</tr>\n<tr>\n<td>Petechiae</td>\n<td>Characteristic</td>\n<td>&nbsp;Rare</td>\n</tr>\n<tr>\n<td>Superficial ecchymosis</td>\n<td>Small and Multiple</td>\n<td>Large and Solitary</td>\n</tr>\n<tr>\n<td>Bleeding from superficial cuts&nbsp;</td>\n<td>Profuse</td>\n<td>Minimal persistent</td>\n</tr>\n<tr>\n<td>Hemarthrosis</td>\n<td>Rare</td>\n<td>Characteristic (most common-knee)</td>\n</tr>\n<tr>\n<td>Deep dissecting hematomas</td>\n<td>Rare</td>\n<td>Characteristic (most common-iliopsoas)</td>\n</tr>\n<tr>\n<td>Laboratory tests</td>\n<td>Bleeding time is prolonged</td>\n<td>PT and/or PTT are prolonged</td>\n</tr>\n<tr>\n<td>Most common</td>\n<td>Inherited: VWD</td>\n<td>\n<p>Inherited: Hemophilia A</p>\n<p>Acquired: Hemorrhagic diathesis of liver disease</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>VWD:&nbsp;von Willebrand disease</p>\n<p>PT: Prothrombin time</p>\n<p>PTT: Partial thromboplastin time</p><hr><h3>Related Pearl: Summary of Laboratory findings in Hemostatic Disorders</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Platelet count</strong></p>\n</td>\n<td>\n<p><strong>Bleeding time</strong></p>\n</td>\n<td>\n<p><strong>PT</strong></p>\n</td>\n<td>\n<p><strong>APTT</strong></p>\n</td>\n<td>\n<p><strong>Comments</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>ITP</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Nomal</p>\n</td>\n<td>\n<p>Auto-Antibodies against IIb-IIIa or Ib-IX</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glanzmann thrombasthenia</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Defect in IIb/IIIa</p>\n<p>Autosomal recessive</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Bernard&ndash; Soulier syndrome</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Defect in Ib/IX</p>\n<p>Autosomal recessive</p>\n<p>Large platelets</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>von Willebrand disease</p>\n</td>\n<td>\n<p>Low or normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>3 subtypes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hemophilia A and B</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>X-linked inheritance</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Liver disease</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Vitamin K deficiency</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>DIC</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increase in fibrin degradation products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Aspirin</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Warfarin</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>&uarr; (Even in</p>\n<p>low dose)</p>\n</td>\n<td>\n<p>&uarr; (Even in</p>\n<p>low dose)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>ITP:&nbsp;Immune thrombocytopenic purpura</p>\n<p>DIC: Disseminated intravasculation coagulation</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1975",
      "difficulty": "easy"
    },
    {
      "text": "A 5-year-old boy was brought with the following finding. His mother says that he had banged his leg against a chair yesterday. He has had similar episodes in the past but they were never this severe. What lab values will you likely find in this boy?",
      "choices": [
        {
          "id": 1,
          "text": "Normal bleeding time, prolonged PT, prolonged aPTT"
        },
        {
          "id": 2,
          "text": "Normal bleeding time, prolonged PT,  normal aPTT"
        },
        {
          "id": 3,
          "text": "Prolonged bleeding time, normal PT, prolonged aPTT"
        },
        {
          "id": 4,
          "text": "Normal bleeding time, normal PT, prolonged aPTT"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In the above clinical scenario,<strong> recurrent hemarthrosis</strong> in a male child is suggestive of <strong>hemophilia</strong>. Normal bleeding time, normal PT, prolonged aPTT is seen in hemophilia A and B.</p>\n<p>Hemophilia A has <strong>decreased factor VIII</strong> activity and<strong>&nbsp;</strong>hemophilia B has <strong>decreased factor IX</strong> activity.</p>\n<p>Note: Prolonged bleeding time, normal PT, prolonged aPTT is seen in <strong>von Willebrand disease.</strong></p><hr><h3>Related Pearl: Coagulation Pathways and its Abnormalities</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/0fedd76b578148fc8ed55da37e66574cx1280x1995.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td><strong>Test results</strong></td>\n<td><strong>Inherited causes</strong></td>\n<td><strong>Acquired causes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged PT </strong></p>\n<p>Evaluates extrinsic pathway factors</p>\n<p>Normal PT: 11-13 seconds</p>\n</td>\n<td>Factor VII deficiency </td>\n<td>\n<p>Mild vitamin K deficiency</p>\n<p>Liver disease</p>\n<p>Warfarin</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Prolonged aPTT </strong></p>\n<p>Evaluates intrinsic pathway factors</p>\n<p>Normal aPTT: 25-35 seconds</p>\n</td>\n<td>\n<p>Factors VIII, IX, XI deficiency</p>\n<p>Factor XII, prekallikrein, or HMW kininogen deficiency</p>\n<p>von Willebrand disease</p>\n</td>\n<td>Heparin, lupus anticoagulant, acquired von Willebrand disease</td>\n</tr>\n<tr>\n<td>\n<p>Prolonged PT + prolonged aPTT</p>\n<p>Evaluates common pathway factors</p>\n</td>\n<td>\n<p>Prothrombin (II), fibrinogen (I), factors V and factor X deficiencies</p>\n</td>\n<td>\n<p>Disseminated intravascular coagulation (DIC)</p>\n<p>Severe liver disease</p>\n<p>Severe vitamin K deficiency</p>\n<p>Direct thrombin inhibitor-argatroban, dabigatran</p>\n<p>Direct factor Xa inhibitor-rivaroxaban, apixaban, edoxaban</p>\n<p>Fondaparinux</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p> </p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/6359e01906c647fc90ca09a466f82172.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4049",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is false about acquired hemophilia A?",
      "choices": [
        {
          "id": 1,
          "text": "Autoantibodies are formed against factor VIII"
        },
        {
          "id": 2,
          "text": "Bethesda assay confirms the diagnosis"
        },
        {
          "id": 3,
          "text": "It presents in childhood or early adulthood"
        },
        {
          "id": 4,
          "text": "It may be associated with lymphoproliferative malignancies"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Acquired hemophilia A</strong> occurs predominantly in<strong> older adults</strong> (median age- 60 years).</p>\n<p>It occasionally occurs in pregnant or postpartum women.</p>\n<p>It is an <strong>acquired immune-mediated disease</strong> characterized by <strong>autoantibodies</strong> against <strong>clotting factor VIII</strong>.&nbsp;It is associated with an underlying disease in 50% of patients. They include:</p>\n<ul>\n<li><strong>Malignancies</strong> - lymphomas, prostate cancer</li>\n<li><strong>Dermatologic diseases</strong> - pemphigoid</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4026",
      "difficulty": "medium"
    },
    {
      "text": "In a patient with hemophilia A, how much can infusion of one unit of factor VIII/kg increase the plasma levels of factor VIII?",
      "choices": [
        {
          "id": 1,
          "text": "30%"
        },
        {
          "id": 2,
          "text": "20%"
        },
        {
          "id": 3,
          "text": "10%"
        },
        {
          "id": 4,
          "text": "2%"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>One unit of factor VIII/kg</strong> body weight<strong> increases</strong> the plasma levels of factor VIII levels by <strong>2%</strong>. Therefore, for a rise in 1 % in the plasma, half unit/ kg will be required, that is 0.5 units/kg.</p>\n<p>It is used in the treatment of hemophilia. One unit of FVIII is the amount of FVIII in 1 mL of plasma.</p>\n<p>The dose required for replacement is calculated as :</p>\n<ul>\n<li><strong>Factor VIII dose</strong> = (Target factor VIII levels - baseline factor VIII levels) x bodyweight x 0.5 units/ kg</li>\n<li><strong>Factor IX&nbsp;</strong>(IU) = (Target FIX levels &ndash; FIX baseline levels) x bodyweight (kg) x 1 unit/kg</li>\n</ul>\n<p>Cryoprecipitate is used when factor concentrates are not available. Each bag of cryoprecipitate contains 80 IU of Factor VIII.</p><table>\n<tbody>\n<tr>\n<td><strong>Blood components</strong></td>\n<td><strong>Composition</strong></td>\n<td><strong>Indications</strong></td>\n</tr>\n<tr>\n<td>Factor VIII concentrates</td>\n<td>Factor VIII</td>\n<td>Hemophilia&nbsp;A</td>\n</tr>\n<tr>\n<td>Factor IX concentrates</td>\n<td>Factor IX</td>\n<td>Hemophilia B</td>\n</tr>\n<tr>\n<td>Cryoprecipitate</td>\n<td>\n<p>Fibrinogen</p>\n<p>Factor XIII</p>\n<p>Factor&nbsp;VIII</p>\n<p>VWF</p>\n</td>\n<td>\n<p>Fibrinogen deficiency, Factor XIII deficiency, von Willebrand disease</p>\n</td>\n</tr>\n<tr>\n<td>Fresh frozen plasma (FFP)</td>\n<td>\n<p>Coagulation factors</p>\n<p>Protein C</p>\n<p>Protein&nbsp; S</p>\n<p>Antithrombin</p>\n</td>\n<td>\n<p>Deficiency of prothrombin, factor V, factor VII, factor X, factor XI</p>\n</td>\n</tr>\n<tr>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4024",
      "difficulty": "hard"
    },
    {
      "text": "What effect does desmopressin have when given to patients with coagulation disorders?",
      "choices": [
        {
          "id": 1,
          "text": "Increases factor VIII"
        },
        {
          "id": 2,
          "text": "Increases factor IX"
        },
        {
          "id": 3,
          "text": "Increases factor XI"
        },
        {
          "id": 4,
          "text": "Increases factor VII"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Desmopressin</strong> causes a <strong>transient rise</strong> in<strong>&nbsp;factor VIII</strong> and <strong>von Willebrand factor</strong> (VWF) hence it is given in mild and moderate hemophilia A.</p>\n<p>It does not improve factor VIII levels in severe hemophilia A patients because there are no stores to release. Repeated dosing leads to <strong>tachyphylaxis</strong>.</p>\n<p>It does not increase factor IX levels.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4045",
      "difficulty": "medium"
    },
    {
      "text": "A teenager with hemophilia A presented with multiple spontaneous bleeds. He has been receiving prophylactic factor VIII infusion on a regular basis. Investigations revealed low factor VIII levels and abnormal plasma mixing study. Which of the following can be used to confirm the diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "1,3 beta D glucan assay"
        },
        {
          "id": 2,
          "text": "Platelet activation assay"
        },
        {
          "id": 3,
          "text": "Serotonin release assay"
        },
        {
          "id": 4,
          "text": "Bethesda assay"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>&nbsp;<strong>Bethesda assay</strong> is the best test for the <strong>confirmation</strong> of <strong>factor VIII inhibitors</strong>.&nbsp;</p>\n<p>The formation of<strong> inhibitor/ alloantibodies</strong> to FVIII or FIX is the <strong>major complication </strong>of hemophilia treatment. When this happens, patients do not respond to factor replacement at therapeutic doses.</p>\n<p><strong>aPTT measurement</strong>&nbsp;is done on a <strong>mixed sample</strong>.&nbsp;It is used to <strong>determine</strong> the <strong>presence </strong>of <strong>factor VIII inhibitors.&nbsp;</strong>aPTT is estimated using a 1:1 mix of patient's plasma and normal plasma. It is interpreted as:</p>\n<ul>\n<li>In <strong>hemophilia,</strong> aPTT is <strong>corrected</strong> with a 1:1 mix.&nbsp;</li>\n<li>In patients with <strong>inhibitors</strong>, aPTT with 1:1 mix is <strong>abnormally prolonged</strong> (inhibitor neutralizes the normal factors).</li>\n</ul>\n<p><strong>Bethesda assay </strong>is based on the same principle but is superior because it helps to<strong> quantify</strong> the type and specificity of the inhibitor.</p>\n<p>Option A: 1,3 beta D glucan assay is designed to diagnose<strong> invasive fungal infections</strong> (IFIs).</p>\n<p>Options B and C: It is used to diagnose heparin-induced thrombocytopenia.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1978",
      "difficulty": "medium"
    },
    {
      "text": "Which among the following is wrong about DIC?",
      "choices": [
        {
          "id": 1,
          "text": "Increased schistocytes"
        },
        {
          "id": 2,
          "text": "Increased PT"
        },
        {
          "id": 3,
          "text": "Increased fibrinogen"
        },
        {
          "id": 4,
          "text": "Increased FDPs"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>In disseminated intravascular coagulopathy (DIC), <strong>fibrinogen levels</strong> are<strong> decreased</strong>&nbsp;due to increased bleeding.&nbsp;</p>\n<p>Disseminated intravascular coagulation (DIC) is an <strong>acquired</strong> syndrome characterized by the <strong>widespread activation</strong> of blood clotting factors within blood vessels, resulting in a loss of clotting control. The primary mechanism of DIC involves the uncontrolled generation of <strong>thrombin</strong> through multiple pathways which leads to sustained <strong>coagulation activation</strong>, the formation of <strong>fibrin</strong>, and the consumption of clotting factors and platelets.</p>\n<p><strong>Infections</strong> are the most frequent cause of DIC.</p>\n<p><strong>Laboratory investigations in DIC:</strong></p>\n<ul>\n<li>Decreased platelet count&nbsp;</li>\n<li>Prolonged PT/TT</li>\n<li>Prolonged activated partial thromboplastin time (aPTT)</li>\n<li>Decreased fibrinogen</li>\n<li>Elevated fibrin degradation products (D-dimers)</li>\n<li>Peripheral smear: microangiopathic hemolytic anemia in DIC with schistocytes (fragmented red blood cells)&nbsp;</li>\n</ul>\n<p>The treatment involves <strong>platelet</strong> <strong>transfusion</strong> when platelet counts are <strong>below 10,000-20,000/</strong>&mu;L. Replacement of fibrinogen and coagulation factors is with<strong> fresh frozen plasma (FFP) </strong>along with <strong>cryoprecipitate</strong> or <strong>fibrinogen</strong> <strong>concentrate</strong>.</p>\n<p>In cases of low-grade DIC associated with solid tumors or acute promyelocytic leukemia <strong>low</strong> doses of <strong>continuous-infusion heparin</strong> has been effective.</p><hr><h3>Related Pearl: Parameters of the coagulation pathway and its uses</h3><p><strong> Parameters of the coagulation pathway and its uses</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>Parameter </strong></td>\n<td><strong>Uses</strong></td>\n</tr>\n<tr>\n<td>Prothrombin Time (PT)</td>\n<td>It is used to monitor the functioning of the extrinsic and the common coagulation pathways. Normal PT is 11–13 seconds.</td>\n</tr>\n<tr>\n<td>Activated partial thromboplastin time (aPTT)</td>\n<td>It is used to monitor the functioning of the intrinsic and the common coagulation pathways. Normal aPTT is 25–35 seconds. A relatively rare cause of prolonged aPTT is the presence of antibodies against coagulation plasma proteins called inhibitors. It can be seen due to the following reasons: Hemophilia A and B patients receiving clotting factors to control their bleeding episodes, Pregnancy, Autoimmune diseases, Malignancies (lymphoma, prostate cancer), and Dermatologic conditions.</td>\n</tr>\n<tr>\n<td>Thrombin time (TT)</td>\n<td>It is used for testing the conversion of fibrinogen into fibrin and depends on adequate fibrinogen levels. </td>\n</tr>\n<tr>\n<td>Bleeding time (BT)</td>\n<td>It is the time taken for a standardized skin puncture to stop bleeding. It tests the ability of blood vessels to constrict and platelets to form a hemostatic plug. </td>\n</tr>\n<tr>\n<td>Fibrin degradation products (FDPs)</td>\n<td>They are used to assess the fibrinolytic activity, and they are increased in disseminated intravascular coagulation (DIC). </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><hr><h3>Related Pearl: Summary of Laboratory findings in Hemostatic Disorders</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Disease</strong></p>\n</td>\n<td>\n<p><strong>Platelet count</strong></p>\n</td>\n<td>\n<p><strong>Bleeding time</strong></p>\n</td>\n<td>\n<p><strong>PT</strong></p>\n</td>\n<td>\n<p><strong>APTT</strong></p>\n</td>\n<td>\n<p><strong>Comments</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>ITP</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Nomal</p>\n</td>\n<td>\n<p>Auto-Antibodies against IIb-IIIa or Ib-IX</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Glanzmann thrombasthenia</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Defect in IIb/IIIa</p>\n<p>Autosomal recessive</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Bernard&ndash; Soulier syndrome</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Defect in Ib/IX</p>\n<p>Autosomal recessive</p>\n<p>Large platelets</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>von Willebrand disease</p>\n</td>\n<td>\n<p>Low or normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>3 subtypes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hemophilia A and B</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>X-linked inheritance</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Liver disease</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Vitamin K deficiency</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>DIC</p>\n</td>\n<td>\n<p>Decreased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increase in fibrin degradation products</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Aspirin</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Increased</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p>Warfarin</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>Normal</p>\n</td>\n<td>\n<p>&uarr; (Even in</p>\n<p>low dose)</p>\n</td>\n<td>\n<p>&uarr; (Even in</p>\n<p>low dose)</p>\n</td>\n<td>&nbsp;</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>ITP:&nbsp;Immune thrombocytopenic purpura</p>\n<p>DIC: Disseminated intravasculation coagulation</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5306",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following are risk factors that can cause disseminated intravascular coagulation in patients?<div class='question-desc-html'><ol>\n<li>Gram-positive sepsis</li>\n<li>Chronic pancreatitis</li>\n<li>Adenocarcinoma of prostate</li>\n<li>Snakebite</li>\n<li>Abruptio placentae</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "1,4"
        },
        {
          "id": 2,
          "text": "1,2,4,5"
        },
        {
          "id": 3,
          "text": "2,5"
        },
        {
          "id": 4,
          "text": "1,3,4,5"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Acute pancreatitis can cause disseminated intravascular coagulation (DIC) not chronic pancreatitis.</p>\n<p><strong>Common causes of DIC:</strong></p>\n<ul>\n<li><strong>Sepsis</strong>- gram-positive and gram-negative bacteria, viral, mycotic, parasitic, rickettsial</li>\n<li>Acute pancreatitis</li>\n<li>Trauma, burns</li>\n<li>Malignancies- acute promyelocytic leukemia, <strong>adenocarcinoma</strong> of pancreas and prostate</li>\n<li>Obstetric- <strong>abruptio placentae</strong>, amniotic fluid embolism, and septic abortion</li>\n<li><strong>Snakebite</strong></li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4040",
      "difficulty": "medium"
    },
    {
      "text": "A 33-year-old woman with a twin pregnancy was admitted for normal delivery. After medical induction of labor, she started to bleed profusely from her rectum, vagina, and IV sites. She became hypotensive, tachycardic, and pulses were feeble. Which of the following laboratory findings will you see in her case?",
      "choices": [
        {
          "id": 1,
          "text": "Option 2"
        },
        {
          "id": 2,
          "text": "Option 3"
        },
        {
          "id": 3,
          "text": "Option 1"
        },
        {
          "id": 4,
          "text": "Option 4"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>In the above clinical scenario, the patient seems to have <strong>disseminated intravascular coagulation </strong>(DIC) due to <strong>amniotic fluid embolism</strong> following medical induction of labor.&nbsp;</p>\n<p>Disseminated intravascular coagulation (DIC) is a condition characterized by widespread <strong>intravascular fibrin formation</strong>. The central mechanism is the <strong>uncontrolled</strong> <strong>generation</strong> of <strong>thrombin</strong> by exposure of blood to pathologic levels of tissue factor.</p>\n<p>Lab abnormalities in DIC:</p>\n<ul>\n<li><strong>Low platelet count</strong></li>\n<li>Low fibrinogen</li>\n<li>Prolonged PT and aPTT</li>\n<li><strong>Increased D-dimer</strong></li>\n<li>Increased fibrin-degradation products</li>\n<li>Decreased protein C</li>\n<li><strong>Decreased antithrombin III</strong></li>\n<li><strong>Increased thrombin-antithrombin complex</strong></li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/264aef213a1d4e52a22f049b24fc9f8dx1280x1953.JPEG\" alt=\"Explanation Image\">",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/78f95b6a8a4540cea635d79c411de126.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4032",
      "difficulty": "medium"
    },
    {
      "text": "The most sensitive test for disseminated intravascular coagulation is _____.",
      "choices": [
        {
          "id": 1,
          "text": "Fibrin degradation products level"
        },
        {
          "id": 2,
          "text": "PTT and thrombin time"
        },
        {
          "id": 3,
          "text": "D-dimer assay"
        },
        {
          "id": 4,
          "text": "Platelet count and fibrinogen levels"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The <strong>most sensitive</strong> test for&nbsp;disseminated intravascular coagulation (DIC) is&nbsp;<strong>FDP</strong>&nbsp;(fibrinogen degradation products) level.</p>\n<table>\n<tbody>\n<tr>\n<td>Diagnostic test</td>\n<td>Diagnostic efficiency</td>\n<td>Sensitivity</td>\n<td>Specificity</td>\n</tr>\n<tr>\n<td>FDP and D-dimer combination</td>\n<td>95%</td>\n<td>91%</td>\n<td>94%</td>\n</tr>\n<tr>\n<td><strong>FDP</strong></td>\n<td>87%</td>\n<td><strong>100%</strong></td>\n<td>67%</td>\n</tr>\n<tr>\n<td>PT/PTT and FDP&nbsp;&nbsp;combination</td>\n<td>86%</td>\n<td>91%</td>\n<td>71%</td>\n</tr>\n<tr>\n<td>D-dimer</td>\n<td>80%</td>\n<td>91%</td>\n<td>68%&nbsp;</td>\n</tr>\n<tr>\n<td>PT, PTT, thrombin time, platelet count, fibrinogen, and the presence of schistocytes</td>\n<td>57%, 57%, 70%, 67%, 65%, and 51%, respectively</td>\n<td>&nbsp;low</td>\n<td>&nbsp;low</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4037",
      "difficulty": "medium"
    },
    {
      "text": "A 3-year-old child is brought to the emergency with petechiae, bruising, and abdominal distension. Examination revealed an abdominal mass.  Investigations revealed schistocytes and thrombocytopenia. What is the most probable cause of the mass?",
      "choices": [
        {
          "id": 1,
          "text": "Neuroblastoma"
        },
        {
          "id": 2,
          "text": "Hepatoblastoma"
        },
        {
          "id": 3,
          "text": "Wilm's tumor"
        },
        {
          "id": 4,
          "text": "Hepatic hemangioma"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>This patient presents with <strong>petechiae,</strong> and abdominal distension with schistocytes and thrombocytopenia. This in child most likely has <strong>Kasabach-Merritt syndrome</strong> (secondary DIC). His abdominal mass is likely to be a <strong>hepatic hemangioma.</strong> </p>\n<p><strong>Kasabach-Merritt syndrome</strong> is a life-threatening complication that occurs in patients with <strong>giant hemangiomas</strong>. It is most commonly seen in<strong> infants</strong>. </p>\n<p>Clinical features: </p>\n<ul class=\"i8Z77e\">\n<li class=\"TrT0Xe\">Enlarged abdomen</li>\n<li class=\"TrT0Xe\">Hepatomegaly or jaundice</li>\n<li class=\"TrT0Xe\">Petechiae, bruising, and frank bleeding</li>\n<li class=\"TrT0Xe\">Painful lesions</li>\n<li class=\"TrT0Xe\">Anemia</li>\n</ul>\n<p>It is characterized by profound <strong>thrombocytopenia and consumptive coagulopathy</strong> leading to a DIC-like picture.</p>\n<p>Other options: </p>\n<p>Option A: <strong>Neuroblastomas</strong> are tumors of the sympathetic ganglia and adrenal medulla that are derived from primordial neural crest cells. It is the most common extracranial solid tumor of childhood and the most frequently diagnosed tumor in infancy. Brain tumors are the most common solid tumors in childhood. They present as a <strong>flank mass</strong> that crosses the <strong>midline.</strong></p>\n<p>Option B: <strong>Hepatoblastoma</strong> is the most common childhood liver tumor. Histologically it is composed of small polygonal embryonal cells forming trabeculae, acini, or papillary structures in the developing liver.</p>\n<p>Option C: <strong>Wilms</strong> tumor is the most common primary malignant renal tumor in children and is the second most common malignant abdominal tumor in children. The clinical presentation usually involves an asymptomatic <strong>unilateral abdominal mass,</strong> hypertension, abdominal pain, and gross painless hematuria. Constitutional symptoms of fever, anorexia, and weight loss can also be present at the time of diagnosis. </p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4042",
      "difficulty": "medium"
    },
    {
      "text": "Patients with protein C deficiency are at an increased risk of developing all of the following except:",
      "choices": [
        {
          "id": 1,
          "text": "Deep vein thrombosis"
        },
        {
          "id": 2,
          "text": "Purpura fulminans"
        },
        {
          "id": 3,
          "text": "Warfarin-induced skin necrosis"
        },
        {
          "id": 4,
          "text": "Spontaneous bleeding"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Spontaneous bleeding is not seen in protein C deficiency. It is characterised by an&nbsp;<strong>increased </strong>tendency for <strong>thrombus formation</strong>.</p>\n<p><strong>Protein C deficiency</strong> is a rare genetic disorder.&nbsp;It predisposes to the following thrombotic complications:</p>\n<ul>\n<li><strong>Deep vein thrombosis </strong>(DVT):\n<ul>\n<li>Adults with a mild form of the disease at higher risk of developing venous thromboembolism.</li>\n</ul>\n</li>\n<li><strong>Purpura fulminans</strong>:\n<ul>\n<li>Severe form of <strong>DIC</strong></li>\n<li>Thrombosis of extensive areas of the skin</li>\n<li>Affects predominantly young children following viral or bacterial infection.&nbsp;</li>\n</ul>\n</li>\n<li><strong>Warfarin-induced skin necrosis:</strong>\n<ul>\n<li>Rare complication seen in patients with congenital or acquired deficiencies of protein C or S.</li>\n<li>Thrombosis of the skin leads to well-demarcated erythematous lesions with central necrosis on the thighs, buttocks, breasts, or toes(shown below).</li>\n</ul>\n</li>\n</ul><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6ad8b3fbe45c4161a1887693df8a08aex416x501.PNG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1754",
      "difficulty": "medium"
    },
    {
      "text": "A patient is on prophylactic unfractionated heparin for deep vein thrombosis. Which of the following tests can be used to monitor its anticoagulant effect?",
      "choices": [
        {
          "id": 1,
          "text": "Prothrombin time"
        },
        {
          "id": 2,
          "text": "Anti-Factor Xa level"
        },
        {
          "id": 3,
          "text": "PT and Anti-Factor Xa level"
        },
        {
          "id": 4,
          "text": "No monitoring is required"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The <strong>anticoagulant effect </strong>of heparin can be monitored using <strong>anti-factor Xa level</strong> and activated partial thromboplastin time (aPTT).&nbsp;aPTT is prolonged as heparin inhibits intrinsic pathway factors.</p>\n<p><strong>Prothrombin time</strong> and <strong>INR</strong> are used to monitor the anticoagulant effect of <strong>warfarin </strong>(inhibits vitamin K dependent factor II, VII, IX, X. Factor VII has the shortest half-life).</p>\n<p>No monitoring is required with the use of low molecular weight heparin (LMWH) and fondaparinux.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1985",
      "difficulty": "hard"
    },
    {
      "text": "Which of the following is false about low molecular weight heparin?",
      "choices": [
        {
          "id": 1,
          "text": "Higher risk of of bleeding than heparin"
        },
        {
          "id": 2,
          "text": "No laboratory monitoring is required"
        },
        {
          "id": 3,
          "text": "Lower risk of  heparin induced thrombocytopenia"
        },
        {
          "id": 4,
          "text": "Protamine sulphate is only partially effective against low molecular weight heparin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>Low molecular weight heparin (LMWH) has a <strong>lower risk of bleeding</strong> than heparin.</p>\n<p>In contrast<strong>&nbsp;</strong>to heparin which requires monitoring by aPTT and anti-factorXa, <strong>laboratory monitoring</strong> is <strong>not required</strong> for LMWH. It is also associated with<strong> lower risk</strong> of <strong>heparin induced thrombocytopenia</strong>.</p>\n<p>Examples of LMWH:</p>\n<ul>\n<li>Dalteparin</li>\n<li>Enoxaparin</li>\n<li>Tinzaparin</li>\n<li>Nadroparin</li>\n</ul>\n<p><strong>Protamine sulphate</strong> is the only clinically approved <strong>antidote</strong> for unfractionated heparin. Protamine sulphate is only partially effective against low molecular weight heparin.</p><hr><h3>Related Pearl: Classification of Anticoagulants</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b14dd7e06cd44c95a1d5289e3a32ad8ax1280x1944.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Classification of anticoagulants</strong></td>\n</tr>\n<tr>\n<td>1) Vitamin K antagonist</td>\n<td>Warfarin</td>\n</tr>\n<tr>\n<td>2) Direct thrombin inhibitors (DTI)&nbsp;&nbsp;&nbsp;</td>\n<td>\n<p><strong>Parenteral:&nbsp;Monovalent</strong> DTI-&nbsp;Argatroban</p>\n<p><strong>Bivalent</strong> DTI- Lepirudin, Desirudin, Bivalirudin</p>\n<p><strong>Oral</strong>:&nbsp;Dabigatran&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>3) Indirect thrombin inhibitors&nbsp;</td>\n<td>\n<p>Unfractionated heparin</p>\n<p>Low molecular weight heparins:&nbsp;Enoxaparin, Dalteparin, Tinzaparin, Nadroparin</p>\n</td>\n</tr>\n<tr>\n<td>4) Indirect factor Xa inhibitors</td>\n<td>Fondaparinux</td>\n</tr>\n<tr>\n<td>5) <strong>Oral</strong> Direct factor Xa inhibitors</td>\n<td>Rivaro<strong>xa</strong>ban,Api<strong>xa</strong>ban, Edo<strong>xa</strong>ban,Betri<strong>xa</strong>ban</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4041",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is a direct thrombin inhibitor?",
      "choices": [
        {
          "id": 1,
          "text": "Apixaban"
        },
        {
          "id": 2,
          "text": "Abciximab"
        },
        {
          "id": 3,
          "text": "Argatroban"
        },
        {
          "id": 4,
          "text": "Edoxaban"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Argatroban</strong> is a parenteral <strong>direct thrombin inhibitor</strong>.</p>\n<p><strong>Apixaban</strong>&nbsp;and edoxaban are a novel oral anticoagulant (NOAC) that inhibits<strong> factor Xa.&nbsp;</strong>Abciximab is an antiplatelet drug that inhibits <strong>Gp IIb-IIIa receptor</strong>.</p><hr><h3>Related Pearl: Classification of Anticoagulants</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b14dd7e06cd44c95a1d5289e3a32ad8ax1280x1944.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Classification of anticoagulants</strong></td>\n</tr>\n<tr>\n<td>1) Vitamin K antagonist</td>\n<td>Warfarin</td>\n</tr>\n<tr>\n<td>2) Direct thrombin inhibitors (DTI)&nbsp;&nbsp;&nbsp;</td>\n<td>\n<p><strong>Parenteral:&nbsp;Monovalent</strong> DTI-&nbsp;Argatroban</p>\n<p><strong>Bivalent</strong> DTI- Lepirudin, Desirudin, Bivalirudin</p>\n<p><strong>Oral</strong>:&nbsp;Dabigatran&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>3) Indirect thrombin inhibitors&nbsp;</td>\n<td>\n<p>Unfractionated heparin</p>\n<p>Low molecular weight heparins:&nbsp;Enoxaparin, Dalteparin, Tinzaparin, Nadroparin</p>\n</td>\n</tr>\n<tr>\n<td>4) Indirect factor Xa inhibitors</td>\n<td>Fondaparinux</td>\n</tr>\n<tr>\n<td>5) <strong>Oral</strong> Direct factor Xa inhibitors</td>\n<td>Rivaro<strong>xa</strong>ban,Api<strong>xa</strong>ban, Edo<strong>xa</strong>ban,Betri<strong>xa</strong>ban</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1988",
      "difficulty": "medium"
    },
    {
      "text": "A patient presented with bleeding gums and skin discoloration. She was given heparin for DVT prophylaxis 5 days ago. Investigations showed thrombocytopenia. Which of the following is the most specific test to diagnose this condition?",
      "choices": [
        {
          "id": 1,
          "text": "4T scoring"
        },
        {
          "id": 2,
          "text": "Platelet activation assay"
        },
        {
          "id": 3,
          "text": "Heparin-PF-4 complex antibody assay"
        },
        {
          "id": 4,
          "text": "Serotonin release assay"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Serotonin release assay</strong>&nbsp;is the <strong>most specific</strong> test for the diagnosis of heparin-induced thrombocytopenia (<strong>HIT</strong>).</p>\n<p>HIT is commonly diagnosed clinically by means of <strong>4T scoring </strong>(<strong>T</strong>hrombocytopenia<strong>,&nbsp;T</strong>iming of platelet count fall, <strong>T</strong>hrombosis,&nbsp;Other causes for<strong>&nbsp;T</strong>hrombocytopenia).</p>\n<p>Serotonin release assay&nbsp;is performed by quantifying serotonin release.</p>\n<div data-canvas-width=\"342.576\">Platelets loaded with labeled serotonin are exposed to patient serum in the absence or presence of varying concentrations of heparin. If the patient serum contains the<strong> HIT antibody</strong>, heparin addition induces <strong>platelet activation</strong>&nbsp;and <strong>serotonin release</strong>.&nbsp;</div>\n<p>Enzyme-linked assays such as platelet activation assay and heparin-PF-4 complex antibody assay are sensitive but not specific for HIT.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MB4021",
      "difficulty": "hard"
    },
    {
      "text": "A 69-year-old male patient with chronic kidney disease presented with bleeding gums and skin rash. He had undergone dialysis 1 week ago. Further investigations revealed heparin-induced thrombocytopenia to be the cause. Which of the following drugs can be given to him?",
      "choices": [
        {
          "id": 1,
          "text": "Lepirudin"
        },
        {
          "id": 2,
          "text": "Argatroban"
        },
        {
          "id": 3,
          "text": "Bivalirudin"
        },
        {
          "id": 4,
          "text": "Fondaparinux"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>In the above clinical scenario, the patient requires <strong>direct thrombin inhibitors</strong> for the treatment of heparin-induced thrombocytopenia.&nbsp;<strong>Argatroban</strong>&nbsp;is<strong>&nbsp;safe</strong>&nbsp;in <strong>renal disease</strong>.</p>\n<p>The<strong> parenteral direct thrombin inhibitors</strong> are:</p>\n<ul>\n<li><strong>Argatroban</strong> - hepatic clearance, approved for the treatment of HIT</li>\n<li><strong>Lepirudin</strong> - renal clearance, contraindicated in renal disease</li>\n<li><strong>Bivalirudin</strong>- renal clearance, contraindicated in renal disease, shortest half-life</li>\n</ul>\n<p>Fondaparinux is a factor Xa inhibitor. It is contraindicated in renal disease because it has renal clearance.</p><hr><h3>Related Pearl: Classification of Anticoagulants</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b14dd7e06cd44c95a1d5289e3a32ad8ax1280x1944.JPEG\" alt=\"Pearl Image\"><table>\n<tbody>\n<tr>\n<td colspan=\"2\"><strong>Classification of anticoagulants</strong></td>\n</tr>\n<tr>\n<td>1) Vitamin K antagonist</td>\n<td>Warfarin</td>\n</tr>\n<tr>\n<td>2) Direct thrombin inhibitors (DTI)&nbsp;&nbsp;&nbsp;</td>\n<td>\n<p><strong>Parenteral:&nbsp;Monovalent</strong> DTI-&nbsp;Argatroban</p>\n<p><strong>Bivalent</strong> DTI- Lepirudin, Desirudin, Bivalirudin</p>\n<p><strong>Oral</strong>:&nbsp;Dabigatran&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>3) Indirect thrombin inhibitors&nbsp;</td>\n<td>\n<p>Unfractionated heparin</p>\n<p>Low molecular weight heparins:&nbsp;Enoxaparin, Dalteparin, Tinzaparin, Nadroparin</p>\n</td>\n</tr>\n<tr>\n<td>4) Indirect factor Xa inhibitors</td>\n<td>Fondaparinux</td>\n</tr>\n<tr>\n<td>5) <strong>Oral</strong> Direct factor Xa inhibitors</td>\n<td>Rivaro<strong>xa</strong>ban,Api<strong>xa</strong>ban, Edo<strong>xa</strong>ban,Betri<strong>xa</strong>ban</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1711",
      "difficulty": "medium"
    },
    {
      "text": "A patient on warfarin develops severe gastrointestinal bleeding. What is the treatment of choice?",
      "choices": [
        {
          "id": 1,
          "text": "Vitamin K slow IV infusion"
        },
        {
          "id": 2,
          "text": "Fresh frozen plasma"
        },
        {
          "id": 3,
          "text": "Vit K and FFP"
        },
        {
          "id": 4,
          "text": "Discontinuation of warfarin only"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Patients on warfarin who present with <strong>severe bleeding</strong> are treated with both<strong> IV infusion of vitamin K</strong> and <strong>fresh frozen plasma</strong> regardless of the INR.</p>\n<p>Warfarin is an oral anticoagulant that blocks the enzyme <strong>vitamin K epoxide reductase</strong>. This&nbsp;inhibits factors <strong>II, VII, IX, and X,&nbsp;</strong><strong>proteins C </strong>and<strong> S.&nbsp;</strong>This can cause an initial procoagulant state.</p>\n<p>Since the anticoagulant action of <strong>warfarin</strong> takes<strong> 2-3 days,</strong> patients require concomitant treatment (bridging therapy) with a rapidly acting parenteral anticoagulant (heparin, LMWH or fondaparinux) for at least&nbsp;5 days.</p>\n<p>Warfarin has a narrow therapeutic window, hence all patients on warfarin should have their <strong>INR determined</strong> every <strong>3&ndash;4 weeks</strong>.&nbsp;The most common side effect of warfarin is bleeding.</p>\n<p>Severe or life-threatening bleed includes:</p>\n<ul>\n<li>Hematuria</li>\n<li>Gastrointestinal bleeding</li>\n<li>Intracranial hemorrhage</li>\n<li>Intramuscular or intra-abdominal bleed</li>\n</ul>\n<p><strong>Management of supratherapeutic INR:</strong></p>\n<table>\n<tbody>\n<tr>\n<td><strong>INR</strong></td>\n<td><strong>Bleeding&nbsp;</strong></td>\n<td><strong>Management</strong></td>\n</tr>\n<tr>\n<td>3.5-10</td>\n<td>No</td>\n<td>Hold warfarin until INR is therapeutic</td>\n</tr>\n<tr>\n<td>&gt;10</td>\n<td>No</td>\n<td>Oral vitamin K 2.5-5 mg</td>\n</tr>\n<tr>\n<td>Any</td>\n<td>Serious or life-threatening</td>\n<td>10 mg vitamin K slow IV infusion + fresh frozen plasma/prothrombin complex concentrate</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1724",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a direct oral anticoagulant ?",
      "choices": [
        {
          "id": 1,
          "text": "Dabigatran"
        },
        {
          "id": 2,
          "text": "Danaparoid"
        },
        {
          "id": 3,
          "text": "Rivoraxaban"
        },
        {
          "id": 4,
          "text": "Edoxaban"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>Danaparoid is not a direct oral anticoagulant (DOAC). It is a<strong> heparinoid</strong> administered via IV or SC routes.</p>\n<p><strong>DOACs</strong> are alternatives to warfarin, easier to administer with fixed doses, and <strong>no requirement for monitoring</strong>.</p>\n<table>\n<tbody>\n<tr>\n<td colspan=\"2\">Direct oral anticoagulants (DOAC)</td>\n</tr>\n<tr>\n<td>Thrombin inhibitors (dabigatran)</td>\n<td>Factor&nbsp;<strong>Xa</strong>&nbsp;inhibitors</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>No CYP2C9 polymorphisms</li>\n<li>A standard dose of 150 mg BD</li>\n<li>No PT/INR monitoring</li>\n<li>Dialyzable</li>\n<li>Mild GI bleeding</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Rivaroxaban</li>\n<li>Apixaban</li>\n<li>Edoxaban</li>\n<li>Betrixaban&nbsp;</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>All DOACs are contraindicated in patients with&nbsp;<strong>metallic/prosthetic heart valves</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1986",
      "difficulty": "medium"
    },
    {
      "text": "In patients with which of the following is dabigatran approved for use?",
      "choices": [
        {
          "id": 1,
          "text": "Elective hip arthroplasty requiring thromboprophylaxis"
        },
        {
          "id": 2,
          "text": "Total knee arthroplasty requiring thromboprophylaxis"
        },
        {
          "id": 3,
          "text": "Metallic heart valve requiring stroke prophylaxis"
        },
        {
          "id": 4,
          "text": "Non-valvular atrial fibrillation requiring stroke prophylaxis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Stroke prophylaxis in<strong> non-valvular atrial fibrillation</strong> is the <strong>only indication</strong> for which all <strong>DOAC</strong>s are approved.&nbsp;All DOACs are contraindicated in patients with <strong>metallic/prosthetic heart valves</strong>.</p>\n<p>Novel oral anticoagulants:</p>\n<table>\n<tbody>\n<tr>\n<td>Thrombin inhibitors&nbsp;</td>\n<td>Factor Xa inhibitors</td>\n</tr>\n<tr>\n<td>\n<ul>\n<li><strong>Dabigatran (oral)&nbsp;</strong></li>\n<li>Argatroban</li>\n<li>Lepirudin</li>\n<li>Desirudin</li>\n<li>Bivalirudin</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Rivaroxaban</li>\n<li>Apixaban</li>\n<li>Edoxaban</li>\n<li>Betrixaban</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>Dabigatran is a direct oral anticoagulant (DOAC).&nbsp;DOACs are alternatives to warfarin, easier to administer with fixed doses, and no requirement for monitoring.</p>\n<p>Only<strong> rivaroxaban</strong> and<strong> apixaban</strong> are licensed for use as thromboprophylaxis after <strong>elective hip</strong> or <strong>knee arthroplasty</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC1753",
      "difficulty": "medium"
    }
  ]
}